EVALUATION OF THE EFFECTIVENESS OF ALTERNATIVE TREATMENTS FOR MENOPAUSAL SYMPTOMS IN POSTMENOPAUSAL WOMEN
https://doi.org/10.21518/2079-701X-2017-2-76-80
Abstract
Menopause is the final cessation of menstrual cycles due to loss of follicular activity of the ovaries. According to the results of a meta-analysis of 36 studies performed in 35 countries, the average age of menopause onset is 48.8 years (95% CI 48,3 – 49,2) with significant fluctuations of this indicator depending on the geographical region of residence of women: lower in Africa, Latin America and middle East countries (47,2–48.4 years) and later in Europe and Australia (50,5–51,2 year) [1]. The number of women in peri- and postmenopausal phase in connection with the increase in life expectancy is increasing. In Russia it is currently more than 21 million. The average age of the menopause onset in Russia ranges from 49 to 51 years, at the same time women live in conditions of estrogen deficit for 1/3 of their life [2, 3].
About the Authors
S. V. Yureneva
Academician Kulakov Scientific Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Russian Federation
Russian Federation
MD,
Moscow
E. I. Ermakova
Academician Kulakov Scientific Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine,
Moscow
References
1. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol, 2014, 43: 1542–1562.
2. Сметник В.П. и соавт. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Климактерий, 2014, 4: 8.
3. Григорян О.Р., Андреева Е.Н. Менопаузальный синдром у женщин с нарушениями углеводного обмена. Научно-практическое руководство (2-е изд., доп.). М., 2011: 60-69.
4. Mishra GD, Dobson AJ. Using longitudinal profiles to characterize women’s symptoms through midlife: results from a large prospective study. Menopause, 2012, 19: 549-555.
5. Gartoulla P, Islam MR, Bell RJ, Davis SR. Prevalence of menopausal symptoms in Australian women at midlife: a systematic review. Climacteric, 2014, 17: 529-539.
6. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric, 2015, 18: 1-9.
7. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric, 2011, 14: 515-528.
8. Duffy O K, Iversen L, Aucott L, Hannaford PC. Factors associated with resilience or vulnerability to hot flushes and night sweats during the menopausal transition. Menopause, 2013, 20: 383-392.
9. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause, 2014, 21(4): 339-46.
10. Thurston RC, Sutton-Tyrrell K, Everson-Rose S, Hess R, Matthews KA. Hot flashes and subclinical disease: findings from the Study of Women’s Health Across the Nation Heart Study. Circulation, 2008, 118: 1234-1240.
11. Lambrinoudaki I, Augoulea A, Armeni E, et al. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric, 2012, 15: 350-357.
12. Thurston RC, Chang Y, Mancuso P, Matthews KA. Adipokines, adiposity,and vasomotor symptoms during the menopause transition: findings from the Study of Women’s Health Across the Nation. Fertil Steril, 2013, 100: 793-800.
13. Lee SW, Jo HH, Kim MR, et al. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet, 2012, 285: 541-548.
14. Herber-Gast Gerrie-Cor M, Mishra G D. Early severe vasomotor menopausal symptoms are associated with diabetes. Menopause, 2014, 21(8): 855-860.
15. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab, 2010, 95(Suppl 1): 1-66.
16. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2012, 19(3): 257-271.
17. de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Climacteric, 2013, 16: 203-4.
18. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews, 2012, 9: CD007244.
19. Рафаэлян И.В., Балан В.Е., Ковалева Л.А. Эффективность и безопасность применения экстракта цимицифуги рацемозы в терапии климактерического синдрома в течение года (результаты собственного исследования). Медицинский совет, 2014, 7: 54-57.
20. Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 2006, 295(17): 2057-71.
21. Hill CA, Harris RC, Kim HJ et al. Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Amino Acids, 2007, 32(2): 225-33.
Review
For citations:
Yureneva SV, Ermakova EI. EVALUATION OF THE EFFECTIVENESS OF ALTERNATIVE TREATMENTS FOR MENOPAUSAL SYMPTOMS IN POSTMENOPAUSAL WOMEN. Meditsinskiy sovet = Medical Council. 2017;(2):76-80. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-76-80
Views:
845
Email this article 